
Patient Experience with Intranasal Esketamine in Treatment-Resistant Depression: Insights from a Multicentric Italian Study (REAL-ESKperience).
Patient experiences with intranasal esketamine show 88.4% report improved quality of life in treatment-resistant depression. ππ§